CLRN1

CLRN1, located on chromosome 3, provides the code for clarin-1, a protein that threads through the cell membrane and is thought to matter for the development and upkeep of the inner ear and the retina. The gene is also known by the names USH3, USH3A and RP61, which reflect the conditions it can cause. An unexpected feature of clarin-1 in the retina is where it is made: studies in mouse and human tissue found it mainly in Müller glia, the supportive cells that span the retina, rather than in the light-detecting photoreceptors themselves. This is unusual, because most proteins linked to retinal degeneration are made in the photoreceptors.

The retinal disease caused by CLRN1 is a rod-cone dystrophy, the pattern seen in retinitis pigmentosa. Rods, the cells responsible for night and side vision, are affected first, so early symptoms often include difficulty seeing in the dark (night blindness) and a gradual narrowing of the visual field. Cones, which handle central and color vision, tend to decline more slowly, so central vision can be retained for a longer time. In a French cohort of four people with CLRN1 variants, doctors described a severe photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) dystrophy with small whitish granular patches around the macula and tiny cysts within the retina, and vision worsened progressively over years of follow-up. Comparisons of USH3A with the related USH2A form suggest that rod loss can progress more rapidly in USH3A. The age of onset, severity and rate of change vary from person to person, so a genetic result alone cannot predict exactly how one individual's vision will progress.

It is well established that CLRN1 variants cause Usher syndrome (definition: A genetic condition that causes both retinitis pigmentosa and hearing loss, sometimes with balance problems.) type 3A, which combines progressive sensorineural hearing loss with retinitis pigmentosa, and in about half of people is accompanied by balance (vestibular) problems. Usher type 3 is the least common of the three main Usher types, accounting for a small share of Usher cases overall, though it is more frequent in certain populations. Founder variants concentrate the disease in some groups, including an N48K change common in people of Ashkenazi Jewish background and a deep intronic founder mutation reported on the Arabian Peninsula. It is now also established that CLRN1 can cause non-syndromic retinitis pigmentosa, meaning retinal disease without hearing loss, as reported in Pakistani families and in other individuals. Laboratory and animal studies point to the Müller glia as central to the disease, with loss of clarin-1 in these support cells leading to secondary damage and death of photoreceptors.

Exactly how the loss of a Müller-glia protein leads to photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) death is still being worked out. One complication for research is that mice lacking Clrn1 develop hearing loss but not the retinal degeneration seen in people, so mouse models do not fully reproduce the human eye disease. Newer models in zebrafish and rabbits reproduce more features of the human retinal disease, but findings in animals and in lab-grown tissue do not automatically translate to people. It also remains incompletely understood why some CLRN1 variants cause the full syndrome with hearing loss while others cause retinitis pigmentosa alone; in at least one case a partially working ("leaky") variant was linked to the non-syndromic form.

As of this review, the supplied evidence does not identify a treatment approved specifically for CLRN1-related retinal disease. In retinal organoids (lab-grown miniature retinas) made from a person with USH3A, CLRN1 variants caused mitochondrial problems in Müller cells, and the antioxidant idebenone partially reduced the damage. This is an early laboratory finding and is not evidence that idebenone is an effective or available treatment for people. In zebrafish, restoring clarin-1 specifically in Müller glia—not in rods or cones—protected photoreceptors, which researchers suggest could guide future gene-based therapies. Separately, a pooled analysis of mouse studies found that gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) delivered to the inner ear improved hearing across several deafness genes including Clrn1, but this addresses hearing in animals rather than vision in people.

• Müller-cell mitochondrial dysfunction in patient-derived organoids

  Laboratory research using patient-derived cells.

  What was found:

  CLRN1 was found in Müller cells, and the variants caused mitochondrial problems there that led to secondary photoreceptor stress and death; idebenone partially reduced the damage.

  Why it matters:

  It suggests a disease mechanism centered on support cells and points to possible therapeutic targets.

  Limitation: This is early lab work; it does not show that idebenone helps people, and organoids do not fully replicate a living eye.

• Zebrafish model shows Müller glia are key to photoreceptor survival

  Animal (zebrafish) laboratory research.

  What was found:

  Restoring clarin-1 in Müller glia—but not in rods or cones—protected photoreceptors from light-induced damage, and the amount of protein mattered.

  Why it matters:

  It supports targeting Müller glia in future gene therapy and helps explain why photoreceptors fail.

  Limitation: Findings in fish may not transfer directly to humans, and this is not a treatment.

• Large-animal (rabbit) model of USH3A retinal degeneration

  Animal (rabbit) laboratory research.

  What was found:

  The rabbits developed progressive retinal thinning on a timeline resembling human disease, with clarin-1 confined to a subset of Müller glia and photoreceptors damaged indirectly.

  Why it matters:

  A model that mimics the human timeline gives researchers a better tool for testing treatments.

  Limitation: Animal results are preliminary and therapeutic strategies described remain experimental.

• Detailed retinal picture in CLRN1-related Usher type 3A

  Observational human case series with long follow-up.

  What was found:

  All had a severe rod-cone dystrophy with a distinctive whitish granular appearance around the macula, cysts within the retina, and progressive loss of vision and visual field over time.

  Why it matters:

  It defines what CLRN1 retinal disease tends to look like, which can help doctors recognize and monitor it.

  Limitation: Only four patients were studied, so the findings may not capture the full range of the disease.

• CLRN1 can cause retinitis pigmentosa without hearing loss

  Human genetic study with supporting cell experiments.

  What was found:

  Novel CLRN1 missense variants caused non-syndromic retinitis pigmentosa, with normal hearing; these were thought to be milder (hypomorphic) changes.

  Why it matters:

  It established that CLRN1 disease is not always syndromic, which affects how a genetic result is interpreted.

  Limitation: Based on two families; the relationship between specific variants and syndromic versus non-syndromic disease is still being clarified.

Unlike many retinal genes, CLRN1 often affects hearing as well as vision, so families may need to plan for the possibility of progressive hearing loss and, in some people, balance difficulties. In Usher type 3, hearing loss typically progresses over time rather than being present at a fixed level from birth, which makes periodic hearing checks worthwhile. Because the condition is autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.), siblings of an affected person can be carriers or affected, and this is something relatives may wish to discuss with a genetic counselor. Beyond these points, the general caregiver guidance shown on every gene page applies.

• Do my CLRN1 variants point to Usher syndrome type 3A or to non-syndromic retinitis pigmentosa, and how confident is that interpretation?
• Have my hearing and balance been assessed, and how often should they be monitored over time?
• What does the pattern seen on my retinal imaging and electroretinography suggest about my current stage?
• Given my variants, what is realistically known about how my vision might change?
• Are there registries or natural-history studies for CLRN1 or Usher type 3 that I could consider?
• What support would you recommend for combined hearing and vision changes if both are involved?

Because CLRN1 can cause either syndromic or non-syndromic disease, it can be helpful to confirm with your care team whether hearing and balance have been formally evaluated. A genetic counselor can explain what your specific variants mean, since the exact change and even the transcript involved can affect interpretation. If you are interested in research, RP Hope's Clinical Trials Finder can help you screen studies with CLRN1 in mind, rather than trying to judge eligibility on your own.